医学
彭布罗利珠单抗
淋巴瘤
美罗华
非霍奇金淋巴瘤
化疗
颈淋巴结病
淋巴结
病理
肿瘤科
内科学
癌症
免疫疗法
疾病
作者
Bismarck Osumo,Joseph Radzevich,N. Nashed,Omar Al Ustwani,Gus J. Slotman
标识
DOI:10.1177/00031348211054526
摘要
Primary lymphomas of the parotid are rare (4-5%) and seldom appear in patients with pre-existing metastatic cancer from other primary sources. We present a primary marginal zone B-cell lymphoma of the mucosaassociated lymphoid tissue (MALT) in an 84-year-old female with preexisting metastatic bladder cancer. A PET scan that identified positive pelvic/cervical lymphadenopathy and bilateral parotid masses. She underwent transurethral resection of a bladder tumor and started on pembrolizumab chemotherapy. After two years, the left parotid mass decreased in size but the right increased to 3.9cm. Right superficial parotidectomy diagnosed B-Cell Marginal zone lymphoma, staining positive for CD20, PAX5, and Bcl2. pembrolizumab was held and the patient was started on 4 weekly rituximab infusions. A PET scan done 3 months after completion of rituximab showed a good response to chemotherapy. This is the first reported case of a primary parotid gland lymphoma in a patient with active metastatic bladder cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI